News

Regular lipoprotein apheresis reduces cardiovascular events

September 15, 2025

Regular lipoprotein apheresis (LA) is associated with a decrease in cardiovascular (CV) events in patients with Lp(a) >60 mg/dL and progressive atherosclerotic cardiovascular disease (ASCVD). This is the finding from the observational multicentre Pro(a)LiFestudy of consecutive patients with high Lp(a) and progressive ASCVD despite effective treatment of other ASCVD risk factors.

Raised Lp(a) linked to carotid artery ulceration

August 15, 2025

Elevated Lp(a) levels are associated with carotid artery ulceration in patients who may be considered candidates for surgical treatment. This was the conclusion of researchers following a study of lipid biomarkers of carotid ulceration in 94 patients with carotid artery stenosis, of whom 38 had confirmed carotid artery ulceration on digital subtraction angiography. 

Elevated Lp(a) adds to healthcare burden in patients with ASCVD

July 23, 2025

People with elevated Lp(a) levels and previous atherosclerotic cardiovascular disease (ASCVD) use more healthcare resources, with greater costs and higher rates of major adverse cardiovascular events (MACE) than those with ASCVD alone, according to healthcare data from Alberta, Canada.

First trimester Lp(a) and poor pregnancy outcomes

June 20, 2025

Pre-eclampsia (PE), foetal growth restriction, gestational hypertension and premature delivery all appear to be more common in women with raised Lp(a) in the first trimester of pregnancy. In a prospective study of 150 pregnant women at less than 12 weeks of foetal gestation with no history of PE, 64.7% of participants with Lp(a) ≥30 mg/dL […]

Brussels Declaration calls for Lp(a) testing in CV health plans 

May 13, 2025

The Brussels International Declaration on Lp(a) testing and management has been published in Atherosclerosis, as a clear roadmap for policymakers to implement practical, life-changing policies and systemic reforms focused on the importance of Lp(a) as an independent causal risk factor for cardiovascular (CV) disease.

Lp(a) testing is cost effective in high income countries

April 1, 2025

A new cost effectiveness analysis of Lp(a) testing for primary prevention, carried out for the FH Europe Foundation as part of the Lp(a) International Taskforce initiative, has demonstrated the potential for major cost savings across 11 high income countries*, together with reductions in cardiovascular events.